Brean Capital Initiates Syneron Medical With Buy

Analysts at Brean Capital initiated coverage on Syneron Medical Ltd. ELOS with a Buy rating. The target price for Syneron Medical is set to $18. Syneron Medical shares have gained 4.41% over the past 52 weeks, while the S&P 500 index has surged 12.99% in the same period. Syneron Medical's shares rose 0.42% to close at $11.85 yesterday.